Fundz
Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Dr. Raolat Abdulai Appointed As Chief Medical Officer At Galvani Bioelectronics

PRIVATEJul 17, 2024almost 2 years ago

Position

Chief Medical Officer

Company

Galvani Bioelectronics

Raolat Abdulai
HertfordBiotechnologyHealth CareMedical

Description

Galvani Bioelectronics is recruiting for a randomized, controlled stage of a clinical feasibility study for patients with Rheumatoid Arthritis (RA) and has received approval from the US Food and Drug Administration (FDA) for this progression. Dr. Raolat Abdulai is joining the company as Chief Medical Officer in August.

Company Information

Company

Galvani Bioelectronics

Location

Hertford, Hertfordshire, United Kingdom

About

Galvani Bioelectronics is a pioneering research and development company dedicated to bringing bioelectronic therapies to patients. The company was formed through a partnership between two global healthcare companies, GSK and Verily Life Sciences, a subsidiary of Alphabet Inc. Galvani is developing therapies through implant-based direct modulation of specific neural signals to organs central in disease. These therapies are designed to be safe, precise in their therapeutic effect, and minimally invasive in their delivery through use of small and efficient wireless electronics and keyhole surgery. Connected software will ensure that patients and physicians can effectively control and optimize the therapy.

Predictive Intelligence
Strategic

ML-powered predictions for Galvani Bioelectronics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.